Wafik S. El-Deiry
Editor-in-chief of Oncotarget. Corresponding author of the study on the effects of ONC-201 and ONC-206 combined with standard therapies for glioblastoma.
Best podcasts with Wafik S. El-Deiry
Ranked by the Snipd community
Aug 9, 2024 • 4min
Combining Regorafenib and TAS102 to Target Gastrointestinal Cancers and Overcome Cancer Stemness
In this discussion, researchers Jun Zhang, Lanlan Zhou, Shuai Zhao, and Wafik S. El-Deiry delve into innovative approaches for tackling refractory metastatic gastrointestinal cancers. They unveil exciting findings on the synergistic effects of the FDA-approved drugs TAS102 and regorafenib. Their research suggests this combination could improve survival rates and combat cancer stemness. With promising preclinical results, they emphasize the need for further clinical studies to validate these advances in cancer treatment.
May 9, 2024 • 9min
SARS-CoV-2 Spike Protein Disrupts p53 Tumor Suppressor Pathway
Researchers Wafik S. El-Deiry and Shengliang Zhang discuss how the SARS-CoV-2 spike protein disrupts the p53 tumor suppressor pathway in cancer cells, potentially compromising its functions and increasing cancer cell viability. They highlight the need for further research to understand the implications of SARS-CoV-2 infection on cancer treatment outcomes.
